Summary: Professor Mari Dezawa is the physician-scientist who identified Muse cells in 2010 at Tohoku University. Her clinical training, research history, and continued publication record form the scientific basis for Dezawa MuseCells® in use today.
Professor Mari Dezawa is a physician and neuroscientist based at Tohoku University in Japan. She is known in the regenerative medicine field for her 2010 discovery of Muse cells, a subpopulation of cells identified within mesenchymal stem cell cultures. Her training and research history provide relevant context for understanding the scientific basis of Dezawa MuseCells®. This background is documented across multiple peer-reviewed publications and institutional records, and it is generally referenced by researchers and physicians when discussing the origin of Muse cell-based products.
Education and Early Career
Dezawa’s clinical and research background spans more than three decades and includes formal medical training, a doctoral research program, and academic appointments at multiple Japanese universities. The following milestones outline her career progression:
- 1989: Earned her medical degree from Chiba University School of Medicine and began clinical training in internal medicine.
- 1995: Completed a Ph.D. in the Department of Histology at Chiba University, focused on neural regeneration.
- 2003: Joined Kyoto University Graduate School of Medicine as associate professor, where she studied methods for converting mesenchymal stem cells into neural and skeletal muscle cells.
- 2008: Appointed professor and chair of the Department of Stem Cell Biology and Histology at Tohoku University Graduate School of Medicine.
- 2010: Published the discovery of Muse cells in the Proceedings of the National Academy of Sciences (PNAS).
Early Research Publications
Dezawa’s early laboratory research, published in the Journal of Clinical Investigation (2004) and Science (2005), examined whether human mesenchymal stem cells could be induced to differentiate into neural and skeletal muscle cells. This research was conducted several years before the Muse cell discovery and is part of the published record supporting her subsequent findings.
The Tohoku University Appointment
In 2008, Dezawa was appointed professor and chair of the Department of Stem Cell Biology and Histology at Tohoku University Graduate School of Medicine. This appointment provided dedicated laboratory resources and institutional support, which were in place at the time her lab identified Muse cells two years later.
The Discovery of Muse Cells
The identification of Muse cells originated from a laboratory observation rather than a planned experiment. While studying cultured bone marrow-derived mesenchymal stem cells, researchers in Dezawa’s lab identified a subpopulation of cells that survived processing conditions not typically tolerated by standard cultured cells.
Documented conditions this subpopulation was able to withstand include:
- Prolonged serum deprivation, a condition that limits nutrient availability to cultured cells.
- Enzymatic digestion, a standard step in cell isolation and processing.
- Hypoxic (low-oxygen) culture conditions, which typically reduce cell viability.
- Extended exposure to isolation reagents used during standard laboratory processing.
Dezawa and her team named this subpopulation Multilineage-differentiating Stress Enduring cells, or Muse cells. The findings were published in PNAS in 2010. A subsequent methodology paper, published in Nature Protocols in 2013, described standardized isolation procedures intended to support reproducibility across laboratories.
Recognition and Continued Research
Dezawa has authored more than 200 peer-reviewed papers across neuroscience, cell biology, and regenerative medicine. Her research on Muse cells has continued past the original 2010 publication, and her work has received the following recognition:
- 2011: Received Japan’s Commendation for Science and Technology, awarded by the Minister of Education, Culture, Sports, Science and Technology.
- 2018: Named a fellow of the U.S. National Academy of Inventors, an honor given to researchers whose work has demonstrated significant real-world application.
- Ongoing: Continued authorship on Muse cell research, including preclinical studies and early-phase human trials conducted in Japan.
- Ongoing: Expanding research interest in Muse cell applications across neurologic, cardiovascular, and orthopedic fields.
This continued publication record is a relevant factor when evaluating the scientific basis of any product or treatment referencing Muse cells, since it reflects an ongoing body of work rather than a single, isolated finding.
Why This Background Is Relevant to Patients
Patients considering regenerative medicine treatments are generally not in a position to review peer-reviewed literature directly. However, understanding the scientific origin of a treatment – who discovered it, how it was studied, and what has been published about it – can provide useful context when evaluating a treatment option.
Dezawa’s documented career includes formal medical training, a discovery process based on laboratory observation and follow-up study, and more than a decade of continued peer-reviewed publication. This background does not address every question a patient may have about a specific treatment, but it does establish a verifiable scientific record that can be reviewed independently by a treating physician.
FAQs
Who is Professor Mari Dezawa? A physician and neuroscientist at Tohoku University in Japan, known for identifying Muse cells in 2010.
What are Muse cells? Multilineage-differentiating Stress Enduring cells, a subpopulation first identified within mesenchymal stem cell cultures.
Where was the discovery originally published? In the Proceedings of the National Academy of Sciences (PNAS) in 2010. A related methodology paper was published in Nature Protocols in 2013.
What academic recognition has Dezawa received? Japan’s Commendation for Science and Technology (2011) and fellowship in the U.S. National Academy of Inventors (2018), among other honors.
Why is a discovery’s scientific background relevant to patients? It provides a basis for evaluating whether a treatment is supported by published, peer-reviewed research.
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.
© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.
